Proinflammatory events in right ventricular damage during pulmonary embolism: Effects of treatment with ketorolac in rats

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 3, 2009, Pages 246-252

  Watts, John A ^a   Gellar, Michael A ^a   Stuart, Lori K ^a   Obraztsova, Maria ^a   Kline, Jeffrey A ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase; Inflammation; Neutrophils; NSAID; Pulmonary embolism; Right ventricle

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; KETOROLAC; MYELOPEROXIDASE; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HEART DISEASE; HEART MUSCLE NECROSIS; HEART RIGHT VENTRICLE FUNCTION; LUNG EMBOLISM; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; RIGHT VENTRICULAR DAMAGE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOKINE CXCL1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; E-SELECTIN; GENE EXPRESSION REGULATION; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KETOROLAC; MALE; MYOCARDIAL CONTRACTION; NEUTROPHIL INFILTRATION; PEROXIDASE; PULMONARY EMBOLISM; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; TROPONIN I; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 70349731954     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181b2b699     Document Type: Article

References (47)

1. Dessap MA, Leon R, Habibi A, et al. Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2008;177:646-653.
2. Dixon B, Campbell DJ, Santamaria JD. Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery. Intensive Care Med. 2008;34:1216-1223.
3. Memtsoudis SG, Rosenberger P, Walz JM. Critical care issues in the patient after major joint replacement. J Intensive Care Med. 2007;22:92-104. (Pubitemid 46552997)
4. White T, Petrisor BA, Bhandari M. Prevention of fat embolism syndrome. Injury. 2006;37:S59-S67.
5. Mirski MA, Lele AV, Fitzsimmons L, et al. Diagnosis and treatment of vascular air embolism. Anesthesiology. 2007;106:164-177. (Pubitemid 46035417)
6. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest. 2004;125:1539-1545. (Pubitemid 38501376)
7. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart. 1997;77:346-349. (Pubitemid 27208175)
8. Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004;110:3276-3280. (Pubitemid 39525077)
9. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479-487. (Pubitemid 27431254)
10. Becattini C, Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost. 2008;100:747-751.
11. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008;29:1569-1577. (Pubitemid 351881988)
12. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 2000;102:211-217. (Pubitemid 30451779)
13. Meyer T, Binder L, Hruska N, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol. 2000;36:1632-1636. (Pubitemid 30826000)
14. Lippi G, Favaloro EJ. Cardiac biomarkers in pulmonary embolism. Thromb Haemost. 2008;99:1134-1136.
15. Stevinson BG, Hernandez-Nino J, Rose G, et al. Echocardiographic and functional cardiopulmonary problems six months after first-time pulmonary embolism in previously healthy patients. Eur Heart J. 2007;28:2517-2524. (Pubitemid 47614277)
16. Kline JA, Hernandez-Nino J, Rose GA, et al. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med. 2006;34:2773-2780. (Pubitemid 44610942)
17. Dack S, Master AM, Horn H, et al. Acute coronary insufficiency due to pulmonary embolism. Am J Med. 1949;7:464-477.
18. Vlahakes GJ, Turley K, Hoffman JI. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation. 1981;63:87-95. (Pubitemid 11213337)
19. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877-905.
20. Zagorski J, Sanapareddy N, Gellar MA, et al. Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats. Physiol Genomics. 2008;34:101-111.
21. Watts JA, Gellar MA, Obraztsova M, et al. Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats. Int J Exp Pathol. 2008;89:389-399.
22. Watts JA, Zagorski J, Gellar MA, et al. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol. 2006;41:296-307. (Pubitemid 44080220)
23. Zagorski J, Gellar MA, Obraztsova M, et al. Inhibition of CINC-1 decreases right ventricular damage caused by experimental pulmonary embolism in rats. J Immunol. 2007;179:7820-7826.
24. Kline JA, Zeitouni R, Marchick MR, et al. Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. Am Heart J. 2008;156:308-314.
25. Nordenholz KE, Mitchell AM, Kline JA. Direct comparison of the diagnostic accuracy of fifty protein biological markers of pulmonary embolism for use in the emergency department. Acad Emerg Med. 2008;15:795-799.
26. Mitchell AM, Nordenholz KE, Kline JA. Tandem measurement of D-dimer and myeloperoxidase of C-reactive protein to effectively screen for pulmonary embolism in the emergency department. Acad Emerg Med. 2008;15:800-805.
27. Smulders YM. Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment? Neth J Med. 2001;58:241-247.
28. Iwadate K, Doi M, Tanno K, et al. Right ventricular damage due to pulmonary embolism: examination of the number of infiltrating macrophages. Forensic Sci Int. 2003;134:147-153. (Pubitemid 36808941)
29. Begieneman MP, van de Goot FR, van der Bilt I, et al. Pulmonary embolism causes endomyocarditis in the human heart. Heart. 2008;94:450-456.
30. Jones AE, Watts JA, Debelak JP, et al. Inhibition of prostaglandin synthesis during polystyrene microsphere-induced pulmonary embolism in the rat. Am J Physiol Lung Cell Mol Physiol. 2003;284:L1072-L1081.
31. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
32. Zagorski J, Debelak J, Gellar M, et al. Chemokines accumulate in the lungs of rats with severe pulmonary embolism induced by polystyrene microspheres. J Immunol. 2003;171:5529-5536. (Pubitemid 37432843)
33. Zagorski J, Wahl SM. Inhibition of acute peritoneal inflammation in rats by a cytokine-induced neutrophil chemoattractant receptor antagonist. J Immunol. 1997;159:1059-1062. (Pubitemid 127484078)
34. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest. 2008;134:606-612.
35. Sohn HY, Krotz F. Cyclooxygenase inhibition and atherothrombosis. Curr Drug Targets. 2006;7:1275-1284.
36. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal antiinflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169:141-149.
37. Ray WA, Varas-Lorenso C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2:155-163.
38. Li Q, Guo Y, Tan W, et al. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation. 2007;116:1577-1584. (Pubitemid 47511421)
39. Abbate A, Santini D, Biondi-Zoccai GG, et al. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart. 2004;90:440-443.
40. Abbate A, Salloum FN, Ockaili RA, et al. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol. 2007;49:416-418. (Pubitemid 47000317)
41. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
42. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
43. Zingarelli B. Nuclear factor-kappaB. Crit Care Med. 2005;33:S414-S416.
44. Zingarelli B, Sheehan M, Wong HR. Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med. 2003;31:S105-S111. (Pubitemid 36143484)
45. Yao KA, Roth AC, Stephenson LL, et al. Effect of ketorolac tromethamine (Toradol) on ischemia-reperfusion injury in skeletal muscle. J Reconstr Microsurg. 1998;14:211-214. (Pubitemid 28201725)
46. Hyers TM, Tricomi SM, Liao JJ. Inhibition of some human neutrophil functions by the cyclooxygenase inhibitor ketorolac tromethamine. J Leukoc Biol. 1992;51:490-495.
47. Bestermann W, Houston MC, Basile J, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005;329:292-305. (Pubitemid 40847697)